CA2234936C - Composition pour traiter une affection intestinale inflammatoire par l'administration de n-acetylglucosamine par le colon et traitement connexe - Google Patents

Composition pour traiter une affection intestinale inflammatoire par l'administration de n-acetylglucosamine par le colon et traitement connexe Download PDF

Info

Publication number
CA2234936C
CA2234936C CA002234936A CA2234936A CA2234936C CA 2234936 C CA2234936 C CA 2234936C CA 002234936 A CA002234936 A CA 002234936A CA 2234936 A CA2234936 A CA 2234936A CA 2234936 C CA2234936 C CA 2234936C
Authority
CA
Canada
Prior art keywords
acetylglucosamine
composition
carrier
bowel
nag
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002234936A
Other languages
English (en)
Other versions
CA2234936A1 (fr
Inventor
Simon Murch
Ian W. French
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GLUCOGENICS PHARMACEUTICALS Inc
Original Assignee
GLUCOGENICS PHARMACEUTICALS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GLUCOGENICS PHARMACEUTICALS Inc filed Critical GLUCOGENICS PHARMACEUTICALS Inc
Priority to CA002234936A priority Critical patent/CA2234936C/fr
Priority to US09/261,194 priority patent/US6046179A/en
Priority to HU0101514A priority patent/HUP0101514A3/hu
Priority to PL99343634A priority patent/PL343634A1/xx
Priority to CZ20003846A priority patent/CZ20003846A3/cs
Priority to JP2000544333A priority patent/JP2002512195A/ja
Priority to EP99907220A priority patent/EP1071432A1/fr
Priority to IL13907299A priority patent/IL139072A0/xx
Priority to PCT/CA1999/000218 priority patent/WO1999053929A1/fr
Priority to AU27092/99A priority patent/AU2709299A/en
Publication of CA2234936A1 publication Critical patent/CA2234936A1/fr
Priority to NO20005223A priority patent/NO20005223L/no
Application granted granted Critical
Publication of CA2234936C publication Critical patent/CA2234936C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
CA002234936A 1998-04-17 1998-04-17 Composition pour traiter une affection intestinale inflammatoire par l'administration de n-acetylglucosamine par le colon et traitement connexe Expired - Fee Related CA2234936C (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CA002234936A CA2234936C (fr) 1998-04-17 1998-04-17 Composition pour traiter une affection intestinale inflammatoire par l'administration de n-acetylglucosamine par le colon et traitement connexe
US09/261,194 US6046179A (en) 1998-04-17 1999-03-03 Composition for and treatment of inflammatory bowel disease by colon administration of N-acetylglucosamine
AU27092/99A AU2709299A (en) 1998-04-17 1999-03-12 Composition for and treatment of inflammatory bowel disease by colon administration of n-acetylglucosamine
CZ20003846A CZ20003846A3 (cs) 1998-04-17 1999-03-12 Kompozice pro léčbu zánětlivého onemocnění střev dávkováním N-acetylglukosaminu do tlustého střeva
JP2000544333A JP2002512195A (ja) 1998-04-17 1999-03-12 Ｎ−アセチルグルコサミンの結腸投与による炎症性腸疾患用の組成物およびその治療
EP99907220A EP1071432A1 (fr) 1998-04-17 1999-03-12 Composition et methode permettant de traiter les affections inflammatoires de l'intestin par administration intra-colique de n-acetylglucosamine
HU0101514A HUP0101514A3 (en) 1998-04-17 1999-03-12 Composition for and treatment of inflammatory bowel disease by colon administration of n-acetylglucosamine
PCT/CA1999/000218 WO1999053929A1 (fr) 1998-04-17 1999-03-12 Composition et methode permettant de traiter les affections inflammatoires de l'intestin par administration intra-colique de n-acetylglucosamine
PL99343634A PL343634A1 (en) 1998-04-17 1999-03-12 Composition for and treatment of inflammatory bowel disease by colon administration of n-acetylglucosamine
IL13907299A IL139072A0 (en) 1998-04-17 1999-03-12 Composition for and treatment of inflammatory bowel disease by colon administration of n-acetylglucosamine
NO20005223A NO20005223L (no) 1998-04-17 2000-10-17 Sammensetning for og behandling av inflammatrisk tarmsykdom ved administrering av N-acetylglucosamin i tykktarmen

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002234936A CA2234936C (fr) 1998-04-17 1998-04-17 Composition pour traiter une affection intestinale inflammatoire par l'administration de n-acetylglucosamine par le colon et traitement connexe

Publications (2)

Publication Number Publication Date
CA2234936A1 CA2234936A1 (fr) 1999-10-17
CA2234936C true CA2234936C (fr) 2004-06-29

Family

ID=4162337

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002234936A Expired - Fee Related CA2234936C (fr) 1998-04-17 1998-04-17 Composition pour traiter une affection intestinale inflammatoire par l'administration de n-acetylglucosamine par le colon et traitement connexe

Country Status (8)

Country Link
EP (1) EP1071432A1 (fr)
JP (1) JP2002512195A (fr)
CA (1) CA2234936C (fr)
CZ (1) CZ20003846A3 (fr)
HU (1) HUP0101514A3 (fr)
IL (1) IL139072A0 (fr)
NO (1) NO20005223L (fr)
PL (1) PL343634A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010518917A (ja) 2007-02-19 2010-06-03 マリン ポリマー テクノロジーズ，インコーポレーテッド 止血組成物及び治療法
KR101098581B1 (ko) * 2009-01-09 2011-12-26 서울대학교산학협력단 Ａｂｈ 항원을 이용한 염증질환 개선용 조성물
MX342912B (es) 2010-04-15 2016-10-19 Marine Polymer Tech Inc Aplicaciones antibacterianas de nanofibras de poli-n-acetilglucosamina.
NZ715595A (en) * 2011-04-15 2017-06-30 Marine Polymer Tech Inc Treatment of disease with poly-n-acetyglucosamine nanofibers
WO2014142938A1 (fr) * 2013-03-15 2014-09-18 Aihol Corporation Formulation pharmaceutique contenant un glycosaminoglycane
US9539265B2 (en) 2013-03-15 2017-01-10 Aihol Corporation Pharmaceutical formulation containing glycosaminoglycan
SI3223797T1 (sl) * 2014-11-26 2020-06-30 Evonik Operations Gmbh Farmacevtski ali nutracevtski sestavek z odpornostjo na vpliv etanola
KR102104507B1 (ko) * 2019-08-23 2020-04-24 브릿지바이오테라퓨틱스(주) 팔미토일-l-프롤릴-l-프롤릴-글리실-l-타이로신 나트륨을 포함하는 약제학적 제제 및 이의 제조방법

Also Published As

Publication number Publication date
HUP0101514A3 (en) 2003-07-28
NO20005223D0 (no) 2000-10-17
JP2002512195A (ja) 2002-04-23
EP1071432A1 (fr) 2001-01-31
HUP0101514A2 (hu) 2001-11-28
CA2234936A1 (fr) 1999-10-17
CZ20003846A3 (cs) 2002-03-13
NO20005223L (no) 2000-11-20
IL139072A0 (en) 2001-11-25
PL343634A1 (en) 2001-08-27

Similar Documents

Publication Publication Date Title
US6046179A (en) Composition for and treatment of inflammatory bowel disease by colon administration of N-acetylglucosamine
ES2393814T3 (es) Una composición farmacéutica oral
Rubinstein Approaches and opportunities in colon-specific drug delivery
EP0097651A1 (fr) Formes dosees orales a liberation retardee contenant du 5-asa.
Chen et al. Local drug delivery systems for inflammatory diseases: Status quo, challenges, and opportunities
CA2234936C (fr) Composition pour traiter une affection intestinale inflammatoire par l'administration de n-acetylglucosamine par le colon et traitement connexe
TWI516285B (zh) 含聚葡萄糖胺的劑型
EP4157998A1 (fr) Gel destiné à être utilisé en endoscopie gastro-intestinale et autres utilisations endodermiques, épidermiques et muqueuses
WO2015018344A1 (fr) Application d'andrographolide dans la préparation d'un produit pharmaceutique pour le traitement d'affection inflammatoire du tube digestif, microgranule d'andrographolide pour la vectorisation de médicaments gastro-résistants et leur procédé de préparation
Onishi et al. Efficacy and toxicity of Eudragit-coated chitosan–succinyl-prednisolone conjugate microspheres using rats with 2, 4, 6-trinitrobenzenesulfonic acid-induced colitis
Ray Advanced colon-specific delivery systems for treating local disorders
TWI446915B (zh) 玻尿酸混合物用於製造治療或預防黏膜相關病變或疾病之組成物的用途
Patel et al. Novel pharmaceutical approaches for colon-specific drug delivery: An overview
Lamprecht et al. Carrier systems for the treatment of inflammatory bowel disease
US9539265B2 (en) Pharmaceutical formulation containing glycosaminoglycan
Purkar et al. A review on colonic drug delivery system
Milabuer et al. Orally administered drug delivery systems to the colon
Paul The role of glucagon in the treatment of biliary tract pathology
Asteria et al. Multiple enterocolic perforations and their possible association with prolonged intake of nimesulide: report of two cases
Ghodratı et al. MUCOADHESIVE POLYMERS IN COLON TARGETED DRUG DELIVERY SYSTEMS: A COMPREHENSIVE REVIEW
Das Pharmacotherapy of inflammatory bowel disease
Singh et al. A Review Study on Novel Drug Delivery System for Colon Targeting
JP4632644B2 (ja) リポポリサッカライドを有効成分とする肛門圧低下外用剤
Khan et al. Colon Specific Drug Delivery System: Innovative Approaches to Treat Colonic Ailments
Pawar et al. A Review On: Colon Targeted Drug Delivery System

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20130417